Publication & Citation Trends
Most Cited Works
Publications
35 total
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer
Cited by 2
Semantic Scholar
Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer OA
Cited by 108
Semantic Scholar
Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer. OA
Cited by 3
Semantic Scholar
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Cited by 165
OpenAlex
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results. OA
Cited by 3
Semantic Scholar
Real-World Tumor Response of Palbociclib in Combination With an Aromatase Inhibitor as First-Line Therapy in Pre/Perimenopausal Women With Metastatic Breast Cancer OA
Cited by 7
Semantic Scholar
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study OA
Cited by 152
Semantic Scholar
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3 OA
Cited by 11
Semantic Scholar
Research Topics
Renal cell carcinoma treatment
(26)
Renal and related cancers
(8)
Cancer Genomics and Diagnostics
(6)
Pancreatic and Hepatic Oncology Research
(5)
Economic and Financial Impacts of Cancer
(5)
Frequent Co-Authors
Affiliations
Northwestern University
Fox Chase Cancer Center
City Of Hope National Medical Center
Cleveland Clinic
Memorial Sloan Kettering Cancer Center